Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CMA1 | P23946 | 3/20 | 0.41 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.40 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
| ▸ | SCN4A | P35499 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30689106 | 0.90 | KMT2A (0.52) | KMT2APOLBSMN1; SMN2NPC1MEN1 | |
| SCHEMBL30689141 | 0.89 | KMT2A (0.56) | KMT2APOLBSMN1; SMN2NPC1MEN1 | |
| SCHEMBL30689134 | 0.88 | KMT2A (0.68) | KMT2APOLBSMN1; SMN2NPC1MEN1 | |
| SCHEMBL29535525 | 0.85 | KMT2A (0.51) | KMT2APOLBSMN1; SMN2NPC1MEN1 | |
| SCHEMBL30689132 | 0.85 | KMT2A (0.53) | KMT2APOLBSMN1; SMN2NPC1MEN1 | |
| SCHEMBL30689111 | 0.85 | ADORA3 (0.51) | KMT2AMEN1LMNANPSR1ALDH1A1 | |
| SCHEMBL29508500 | 0.84 | KMT2A (0.56) | KMT2APOLBSMN1; SMN2NPC1MEN1 | |
| SCHEMBL7146326 | 0.83 | KMT2A (0.58) | KMT2APOLBSMN1; SMN2 | |
| SCHEMBL7551114 | 0.83 | KMT2A (0.58) | KMT2APOLBSMN1; SMN2 | |
| SCHEMBL31124686 | 0.83 | KMT2A (0.61) | KMT2APOLBSMN1; SMN2NPC1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312644-A1 | COMPOUNDS HAVING TRIPLE ACTIVITIES OF THROMBOLYSIS, ANTITHROMBOTIC AND RADICAL SCAVENGING | SHANGHAI LUMOSA THERAPEUTICS CO LTD (CN) | 2023-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312644-A1 | COMPOUNDS HAVING TRIPLE ACTIVITIES OF THROMBOLYSIS, ANTITHROMBOTIC AND RADICAL SCAVENGING | SERPINC1, PLAT, F2 | KMT2A 4034/4885POLB 1539/4885SMN1; SMN2 3174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.